Richard J. Kowalski
Profile
Richard J.
Kowalski worked as a Director of Medical Affairs at Cylex, Inc. from 2010 to 2013.
He was a Principal at Cambridge Biotech Corp.
and a Senior Manager at Osiris Therapeutics, Inc. He holds a doctorate degree from Vanderbilt University and an undergraduate degree from the University of Maryland.
Former positions of Richard J. Kowalski
| Companies | Position | End |
|---|---|---|
Cylex, Inc.
 Cylex, Inc. Medical SpecialtiesHealth Technology Cylex is a privately held global life science company that is in the development and manufacture of in vitrodiagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides a platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD and was founded in 1992 | Chief Tech/Sci/R&D Officer | 2013-11-17 |
| OSIRIS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| Cambridge Biotech Corp. | Corporate Officer/Principal | - |
Training of Richard J. Kowalski
| University of Maryland | Undergraduate Degree |
| Vanderbilt University | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 3 |
|---|---|
Cylex, Inc.
Cylex, Inc. Medical SpecialtiesHealth Technology Cylex is a privately held global life science company that is in the development and manufacture of in vitrodiagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides a platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD and was founded in 1992 | Health Technology |
| Cambridge Biotech Corp. | Health Technology |
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
- Stock Market
- Insiders
- Richard J. Kowalski
